Belite Bio Inc. (NASDAQ:BLTE) on Monday released topline results from the global Phase 3 DRAGON trial of Tinlarebant, marking the first successful pivotal trial in patients with Stargardt disease type 1 (STGD1).The Phase 3 DRAGON trial enrolled 104 patients.STGD1 is an eye disease that leads to progressive vision loss, usually beginning in childhood or young adulthood.Tinlarebant is intended to reduce the accumulation of vitamin A-based toxins (known as bisretinoids) that cause retinal disease in STGD1.Also ...